単回投与点鼻薬デバイスの世界市場 - 2025年～2033年

世界の単回投与点鼻薬デバイス市場は、2023年に3億3,550万米ドルに達し、2033年には5億3,710万米ドルに達すると予測され、予測期間2025年から2033年の間でのCAGRは6.5%で成長します。

単回投与点鼻薬は、あらかじめ計量された1回分の薬剤を含む単位用量デバイスであり、緊急の場面で有用です。従来は注射で投与されていたオピオイドやナロキソンのように、専門的な訓練やヘルスケア専門家への即時アクセスなしに、患者や介護者が救命薬を投与することを可能にします。

市場力学：

促進要因と阻害要因

アレルギー性鼻炎の有病率の増加

世界の単回投与点鼻薬デバイス市場は、鼻づまり、くしゃみ、かゆみを引き起こす慢性疾患であるアレルギー性鼻炎の有病率の上昇により拡大しています。これらのデバイスは、正確な投与と最小限の副作用のために、便利で的を絞った方法を提供し、状態を管理するために不可欠です。アレルギー性鼻炎に対する認識が高まり、患者がより効率的な治療法を求めるようになるにつれて、先進的な点鼻薬の需要は増加の一途をたどっています。革新的な製剤の利用可能性が、この動向をさらに後押ししています。

例えば、World Allergy Organization Journalによると、アレルギー性鼻炎は世界全体で4億人以上が罹患しており、有病率は成人で10％～30％、小児では40％を超えています。

そのため、単回投与点鼻薬デバイスは、使いやすさ、正確な投与、迅速な作用により、アレルギー性鼻炎症状の管理に理想的です。その広範な普及がこれらのデバイスの需要を促進し、先進的な薬剤製剤やデバイス技術への技術革新や投資を促し、市場拡大に拍車をかけています。

患者による誤用と不適切な投与のリスク

世界の単回投与点鼻薬デバイス市場は、患者による誤用や不適切な投与のリスクによる課題に直面しています。これらのデバイスは正確な取り扱いと適用技術を必要とするため、特に小児や高齢者層など、デバイスに不慣れな患者にとっては困難な場合があります。しっかりとした患者教育やトレーニングプログラムの欠如がこの問題をさらに悪化させ、投与量不足や無駄の可能性につながっています。さらに、単回投与デバイスは多回投与用デバイスに比べて医療廃棄物の発生量が多いと考えられており、環境への懸念が高まり、廃棄物管理政策が厳しい地域での採用が阻害されています。これらの課題は市場の成長を妨げ、より優れた設計革新と患者支援イニシアチブの必要性を強調しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • アレルギー性鼻炎の増加
  • 抑制要因
    • 患者による誤用や不適切な投与のリスク
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• 液体鼻スプレー
• 滅菌溶液
• 生理食塩水スプレー
• 粉末鼻スプレー

第7章 素材の種類別

• プラスチック
• ポリエチレン（PE）
• ポリプロピレン（PP）
• ガラス

第8章 用途別

• アレルギー性鼻炎
• 鼻づまり
• 副鼻腔炎
• インフルエンザとワクチン
• その他

第9章 エンドユーザー別

• 病院
• クリニック
• ホームケア設定
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Aptar Pharma
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Nemera
• BD（Becton, Dickinson and Company）
• H&T Presspart
• Bespak by Recipharm
• Rexam Healthcare Packaging
• Silgan Dispensing Systems
• West Pharmaceutical Services, Inc
• Gerresheimer AG
• 3M

第13章 付録

The global single-dose nasal spray devices market reached US$ 335.5 million in 2023 and is expected to reach US$ 537.1 million by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.

Single-dose nasal sprays are unit-dose devices that contain a single, pre-measured dose of medication, making them useful in emergency settings. They allow patients or caregivers to administer life-saving medications without requiring specialized training or immediate access to healthcare professionals, such as opioids or naloxone, which are traditionally administered via injection.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Allergic Rhinitis

The global single-dose nasal spray devices market is growing due to the rising prevalence of allergic rhinitis, a chronic condition causing nasal congestion, sneezing, and itching. These devices offer a convenient, targeted method for precise dosing and minimal side effects, making them essential for managing the condition. As awareness of allergic rhinitis increases and patients seek more efficient treatment options, demand for advanced nasal spray devices continues to rise. The availability of innovative formulations further supports this trend.

For instance, according to World Allergy Organization Journal, Globally, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children.

Hence, Single-dose nasal spray devices are ideal for managing allergic rhinitis symptoms due to their ease of use, precise dosing, and rapid action. Their widespread prevalence drives demand for these devices, encouraging innovation and investments in advanced drug formulations and device technologies, thereby fueling market expansion.

Risk of Misuse and Improper Administration by Patients

The global single-dose nasal spray device market faces challenges due to the risk of misuse and improper administration by patients. These devices require precise handling and application techniques, which can be challenging for patients unfamiliar with them, especially in pediatric and elderly populations. The lack of robust patient education and training programs further exacerbates this issue, leading to potential underdosing or wastage. Additionally, single-dose devices are perceived to generate more medical waste than multi-dose alternatives, raising environmental concerns and deterring adoption in regions with strict waste management policies. These challenges hinder market growth and underscore the need for better design innovation and patient support initiatives.

Segment Analysis

The global single-dose nasal spray devices market is segmented based on product type, material type, end user and region.

Product Type:

Liquid Nasal Sprays segment is expected to dominate the single-dose nasal spray devices market share

The liquid nasal sprays segment holds a major portion of the single-dose nasal spray devices market share and is expected to continue to hold a significant portion of the single-dose nasal spray devices market share during the forecast period.

Liquid nasal sprays are a key segment in the global single-dose nasal spray devices market due to their widespread use in various therapeutic areas, including allergic rhinitis, sinusitis, and emergency treatments like opioid overdose reversal. These sprays are preferred for their rapid onset of action, precision dosing, and ease of use, making them ideal for home-based and outpatient care. Advancements in liquid formulation technology have improved the stability and bioavailability of active ingredients, driving demand for innovative single-dose devices. The increasing adoption of liquid nasal sprays for vaccines and biologics further positions them as a key segment in the market.

End User:

Hospitals segment is the fastest-growing segment in single-dose nasal spray devices market share

The hospitals segment is the fastest-growing segment in the single-dose nasal spray devices market share and is expected to hold the market share over the forecast period.

Hospitals are driving the global single-dose nasal spray devices market growth due to their precision, ease of use, and effectiveness in acute care scenarios. These devices are ideal for emergency departments and critical care units, where timely intervention is crucial. Hospitals are often the first point of contact for patients with chronic conditions, leading to the prescription and adoption of single-dose nasal sprays for ongoing treatment. The growing emphasis on infection control in healthcare facilities further bolsters the demand for single-dose devices, as they reduce the risk of cross-contamination compared to multi-dose alternatives. As hospitals adopt advanced drug delivery technologies, their role in shaping the market trajectory continues to expand.

Geographical Analysis

North America is expected to hold a significant position in the single-dose nasal spray devices market share

North America holds a substantial position in the single-dose nasal spray devices market and is expected to hold most of the market share due to the FDA approvals, product launches, high prevalence of respiratory and allergic conditions, as well as its well-established healthcare infrastructure. The region's focus on self-care and home-based treatments, coupled with widespread patient awareness, drives demand for these devices. Regulatory approvals and investment from leading pharmaceutical companies contribute to the region's growth. Government initiatives to combat opioid overdoses have also accelerated the adoption of single-dose nasal sprays for emergency treatments.

For instance, in August 2024, The U.S. FDA has approved neffy, an epinephrine nasal spray, for emergency treatment of Type I allergic reactions in adult and pediatric patients weighing at least 30 kilograms. Neffy is a single-dose nasal spray used to treat anaphylactic episodes. If symptoms persist or worsen, a second dose may be administered using a new nasal spray. Patients may need emergency medical assistance for monitoring and treatment if further treatment is needed.

Europe is growing at the fastest pace in the single-dose nasal spray devices market

Europe holds the fastest pace in the single-dose nasal spray devices market and is expected to hold most of the market share due to the chronic respiratory diseases, aging populations, and environmental allergen exposure. Advanced healthcare systems, patient-friendly treatment options, and a preference for minimally invasive therapies have boosted the adoption of these products. Strong regulatory frameworks and supportive policies for drug delivery innovations encourage market growth. Europe's commitment to sustainability has led to the development of eco-friendly and biodegradable nasal spray devices, aligning with consumer preferences. Europe's emphasis on preventive healthcare and high-quality medical products further strengthens its market position.

For instance, according to article published in ERS, the UK experiences 585,000 respiratory disease diagnoses annually, with half due to asthma and COPD. IPF prevalence is double previous estimates. Nearly 1 in 5 of the population has a lung disease diagnosis, with the highest prevalence in the North-West and South-West of England. This widespread prevalence also drives innovation and adoption of advanced single-dose nasal sprays for chronic and acute respiratory disease management, contributing to the overall growth of the market in Europe and beyond.

Competitive Landscape

The major global players in the single-dose nasal spray devices market include Aptar Pharma, Nemera, BD (Becton, Dickinson and Company), H&T Presspart, Bespak by Recipharm, Rexam Healthcare Packaging, Silgan Dispensing Systems, West Pharmaceutical Services, Inc, Gerresheimer AG, 3M Drug Delivery Systems and among others.

Key Developments

• In October 2024, Birmingham Biotech LTD has launched NoriZite Nasal Spray, a user-friendly nasal device designed to block and trap inhaled virus particles. The device coats the nasal cavity, creating a strong barrier to physically trap and remove viruses before they can cause infection.
• In August 2024, The FDA has approved the first-ever epinephrine single dose nasal spray for emergency treatment of severe allergic reactions, offering a needle-free, fast-acting alternative that could revolutionize anaphylaxis management and save lives. This groundbreaking innovation marks the most significant advance in allergy care in over three decades, offering a needle-free alternative to traditional injectable epinephrine.

Emerging Players

The emerging players in the single-dose nasal spray devices market include Portal Instruments, E3D (Engineered 3D), Medicon Pharma, Perlen Packaging and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global single-dose nasal spray devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Material Type
• 3.3. Snippet by Application
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Allergic Rhinitis
  • 4.1.2. Restraints
    • 4.1.2.1. Risk of Misuse and Improper Administration by Patients
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Liquid Nasal Sprays*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Sterile solutions
• 6.4. Saline sprays
• 6.5. Powder Nasal Sprays

7. By Material Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 7.1.2. Market Attractiveness Index, By Material Type
• 7.2. Plastic*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Polyethylene (PE)
• 7.4. Polypropylene (PP)
• 7.5. Glass

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Allergic Rhinitis*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Nasal Congestion
• 8.4. Sinusitis
• 8.5. Influenza and Vaccines
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Clinics
• 9.4. Home Care Settings
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Aptar Pharma*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Nemera
• 12.3. BD (Becton, Dickinson and Company)
• 12.4. H&T Presspart
• 12.5. Bespak by Recipharm
• 12.6. Rexam Healthcare Packaging
• 12.7. Silgan Dispensing Systems
• 12.8. West Pharmaceutical Services, Inc
• 12.9. Gerresheimer AG
• 12.10. 3M

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us